These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24789037)

  • 1. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
    Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
    Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
    [No Abstract]   [Full Text] [Related]  

  • 2. Vemurafenib/dabrafenib and trametinib.
    Rissmann R; Hessel MH; Cohen AF
    Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
    [No Abstract]   [Full Text] [Related]  

  • 3. Trametinib in metastatic melanoma.
    Chopra N; Nathan PD
    Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to BRAF-targeted therapy in melanoma.
    Sullivan RJ; Flaherty KT
    Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib for the treatment of melanoma.
    Jordan EJ; Kelly CM
    Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
    Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
    Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib in melanoma.
    Shaw HM; Nathan PD
    Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new paradigm of systemic therapies for metastatic melanoma.
    Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
    J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
    Lang N; Weisser A; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLX4032 and melanoma: resistance, expectations and uncertainty.
    Roukos DH
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):325-8. PubMed ID: 21417847
    [No Abstract]   [Full Text] [Related]  

  • 19. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
    Wagle N; Emery C; Berger MF; Davis MJ; Sawyer A; Pochanard P; Kehoe SM; Johannessen CM; Macconaill LE; Hahn WC; Meyerson M; Garraway LA
    J Clin Oncol; 2011 Aug; 29(22):3085-96. PubMed ID: 21383288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeted molecular therapies (except immunotherapy)].
    Roux J; Pages C; Lebbé C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.